^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Triple Negative Breast Cancer
    Drug:adavosertib (AZD1775) (WEE1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    CISPLATIN + AZD-1775 In Breast Cancer

    Excerpt:
    ...Median Progression-free Survival (PFS)`Change in pCDC2 After Therapy With AZD1775 in Paired Biopsies`Number of p53 Mutations`Number of of BRCA1/2 Mutation`Number of Patients Have Changes in Markers for DNA Damage`Correlation Between Next Generation Sequencing of Tumors and Participant Outcomes...
    Trial ID:
    NCT03012477
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancers (Basel)
    Title:

    Facilitating Drug Discovery in Breast Cancer by Virtually Screening Patients Using In Vitro Drug Response Modeling

    Published date:
    02/20/2021
    Excerpt:
    AZD-1775, a Wee1 inhibitor, was predicted to have preferential activity in TNBC (p < 2.2 × 10-16) and its efficacy was highly associated with TP53 mutations (p = 1.2 × 10-46).
    DOI:
    10.3390/cancers13040885